Latest Government Procurement News

Overwatch Technologies is seeking A$8 million to fund an ASX listing and expand its drone-enabled maritime intelligence business. The company has A$3.8 million of contracted orders, but has yet to recognise revenue and reported an inaugural loss of A$857,604.

Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.

Thrive Tribe Technologies has repositioned WooBoard and REFFIND towards defence and workforce software, but its FY26 annual report flags a material uncertainty over the company’s ability to continue as a going concern. The pivot follows a $3.66 million loss, $2.57 million operating cash outflow and another $1 million placement after year-end.

archTIS delivered a sharp step-up in revenue and recurring income after acquiring Spirion, but the stronger top line came with a $16 million loss and a formal warning over its ability to fund operations. The cybersecurity company now has until late October to extend or refinance a key lending facility.

Dataworks Group delivered a much-improved FY26, with revenue up 24%, operating cash flow turning positive and its Ontario platform entering commercial operation. But the ASX-listed regtech company remains loss-making, carries net liabilities of $1.93 million and says its survival depends on further funding.

Dataworks Group has lodged a prospectus for a non-renounceable entitlement offer targeting A$1.24 million, alongside a committed A$3 million placement. The raising would fund debt repayment, working capital and contract mobilisation, but also materially expand the company’s share count and option pool.

Sovereign Metals says a simple add-on circuit at its Malawi project could generate US$722 million of pre-tax value from monazite by-product recovery. The opportunity is commercially striking, but remains a preliminary scoping result dependent on further testwork, approvals, funding and customer qualification.

archTIS surged to a record FY2026 with Annual Recurring Revenue hitting $14.8 million, driven by major US and Australian Defence wins and expanding its customer base beyond defence.

Aurora Labs marked its commercial debut by delivering AU4 micro gas turbine propulsion systems to Sovereign Propulsion Systems, while securing a $1 million government grant to scale production and formalising a strategic defence partnership with MBDA.

Island Pharmaceuticals has secured a critical collaboration with Texas Biomedical Research Institute to advance dose optimisation for its antiviral Galidesivir, targeting Marburg Virus Disease under the FDA Animal Rule. This second phase complements ongoing USAMRIID efforts and aims to de-risk pivotal study design with data from 32 non-human primates.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.